| 0.06 -0.04 (-40%) | 12-12 15:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.1 |
1-year : | 0.12 |
| Resists | First : | 0.08 |
Second : | 0.11 |
| Pivot price | 0.08 |
|||
| Supports | First : | 0.05 | Second : | 0.04 |
| MAs | MA(5) : | 0.07 |
MA(20) : | 0.08 |
| MA(100) : | 0.13 |
MA(250) : | 0.34 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 33.3 |
D(3) : | 39.4 |
| RSI | RSI(14): 40.9 |
|||
| 52-week | High : | 1.19 | Low : | 0.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PXMD ] has closed above bottom band by 2.3%. Bollinger Bands are 27.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.08 - 0.08 | 0.08 - 0.08 |
| Low: | 0.05 - 0.05 | 0.05 - 0.05 |
| Close: | 0.06 - 0.06 | 0.06 - 0.06 |
PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms. The company's lead product candidate is PAX-101, an intravenous formulation of suramin for various indications, including autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and human african trypanosomiasis. It is also involved in developing PAX-102, an intranasal formulation of suramin for neurologic indications. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York. PaxMedica, Inc. operates as a subsidiary of Tardimed Sciences LLC.
Tue, 03 Sep 2024
PaxMedica Secures Immediate Exercise of Warrants - AccessWire
Fri, 12 Apr 2024
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session - Markets Insider
Thu, 11 Apr 2024
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission - Yahoo Finance
Wed, 22 Nov 2023
PaxMedica Announces Pricing of $7M Public Offering - Yahoo Finance
Mon, 20 Nov 2023
Why Is PaxMedica (PXMD) Stock Down 40% Today? - InvestorPlace
Wed, 09 Aug 2023
PaxMedica, Inc. Announces Second Quarter 2023 Financial Results and Business Update - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 8 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 12.6 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 638 (K) |
| Shares Short P.Month | 552 (K) |
| EPS | 68.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.15 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -258.3 % |
| Return on Equity (ttm) | -975.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0.37 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|